Shamburg News · 8-K filed Nov 10, 2026, 4:15 PM EST
NextCure Reports Third Quarter 2026 Results and Business Update on Avere Merger
NXTC · NextCure, Inc.
- Earnings
- Other event
- Materiality: high
NextCure, Inc. reported a net loss of $6.8 million for the quarter ended September 30, 2026, compared to a net loss of $8.6 million for the prior-year quarter. Cash, cash equivalents and marketable securities were $8.7 million at September 30, 2026. The company said financing commitments supporting its proposed merger with Avere Therapeutics increased to approximately $820 million, and a stockholder special meeting is scheduled for December 9, 2026.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001104659-26-125188.
Written from the filing by Shamburg Markets. Figures are as reported by the company.